TY - JOUR
T1 - Treatment of insomnia in depressed insomniacs
T2 - Effects on health-related quality of life, objective and self-reported sleep, and depression
AU - McCall, William Vaughn
AU - Blocker, Jill N.
AU - D'Agostino, Ralph
AU - Kimball, James
AU - Boggs, Niki
AU - Lasater, Barbara
AU - Haskett, Roger
AU - Krystal, Andrew
AU - McDonald, William M.
AU - Rosenquist, Peter B.
PY - 2010/8/15
Y1 - 2010/8/15
N2 - Study Objectives: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was relegated to a secondary outcome, and objective measures of sleep were not undertaken. Design: Double-blind, randomized, placebo-controlled clinical trial Setting: Outpatient clinic and sleep laboratory Patients: 60 depressed, insomniac outpatients Interventions: one week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime Measurements: The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32. Other measures included the Q-LES-Q, self-reported sleep, PSG, actigraphy, depression severity (HRSD) Results: At the end of randomized treatment, patients receiving ESZ had lower (better) DLRF scores (0.81 ± 0.64) than those receiving placebo (1.2 ± 0.72), p = 0.01. The effect size for DLRF was 0.62, indicating a moderate effect. An advantage for ESZ was also seen in other measures of HRQOL, and most assessments of antidepressant efficacy and sleep. Women reported better end of treatment HRQOL scores than men. Conclusions: ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep. ClinicalTrials.gov Identifier: NCT00247624.
AB - Study Objectives: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was relegated to a secondary outcome, and objective measures of sleep were not undertaken. Design: Double-blind, randomized, placebo-controlled clinical trial Setting: Outpatient clinic and sleep laboratory Patients: 60 depressed, insomniac outpatients Interventions: one week of open-label fluoxetine (FLX), followed by 8 more weeks of FLX combined with either eszopiclone (ESZ) 3 mg or placebo at bedtime Measurements: The primary HRQOL measure was the daily living and role functioning subscale (DLRF) of the Basis-32. Other measures included the Q-LES-Q, self-reported sleep, PSG, actigraphy, depression severity (HRSD) Results: At the end of randomized treatment, patients receiving ESZ had lower (better) DLRF scores (0.81 ± 0.64) than those receiving placebo (1.2 ± 0.72), p = 0.01. The effect size for DLRF was 0.62, indicating a moderate effect. An advantage for ESZ was also seen in other measures of HRQOL, and most assessments of antidepressant efficacy and sleep. Women reported better end of treatment HRQOL scores than men. Conclusions: ESZ treatment of insomnia in depressed patients is associated with multiple favorable outcomes, including superior improvement in HRQOL, depression severity, and sleep. ClinicalTrials.gov Identifier: NCT00247624.
KW - Actigraphy
KW - Depression
KW - Eszopiclone
KW - Insomnia
KW - Polysomnography
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=77956289672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956289672&partnerID=8YFLogxK
U2 - 10.5664/jcsm.27872
DO - 10.5664/jcsm.27872
M3 - Article
C2 - 20726279
AN - SCOPUS:77956289672
SN - 1550-9389
VL - 6
SP - 322
EP - 329
JO - Journal of Clinical Sleep Medicine
JF - Journal of Clinical Sleep Medicine
IS - 4
ER -